COCP - Cocrystal Pharma completes single ascending dose of phase 1 study of influenza A drug

• Cocrystal Pharma ( NASDAQ: COCP ) stock has risen 5.4% premarket after it said the single ascending dose portion of the Phase 1 study with its orally administered antiviral candidate CC-42344 for the treatment of pandemic and seasonal influenza A had been completed.
• The company said subjects were currently being enrolled in the multiple ascending dose portion of the Phase 1 study.
• The dose-escalating Phase 1 study being conducted in Australia is intended to assess the safety, tolerability and pharmacokinetics of CC-42344 in healthy adults.
• The trial data showed completed in vitro testing demonstrated potent antiviral activity against prevalent influenza A strains resistant to the two approved influenza treatments Tamiflu and Xofluza.

For further details see: